NRX Pharmaceuticals, Inc.
NRXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001719406
No open-market purchases or sales by NRX Pharmaceuticals, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $47.6M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by NRX Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for NRX Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Casper Joseph Michael | Chief Operating Officer | – | Feb 17, 2026 | 1 |
| Javitt Jonathan C | Chairman and Chief Scientist | 84,634 | Sep 10, 2025 | 0 |
| Hurvitz Chaim | Director | 570,000 | Sep 10, 2025 | 0 |
| Flynn Patrick John | Director | 1,750 | Sep 10, 2025 | 0 |
| McBride Dennis | Director | – | Sep 10, 2025 | 0 |
| Abrams Michael S | Chief Financial Officer | – | Feb 11, 2025 | 0 |
| Gorovitz Aaron | Director | 105,000Indirect | Sep 11, 2023 | 0 |
| Van Voorhees Seth | CHIEF FINANCIAL OFFICER | 46,337 | Dec 19, 2022 | 0 |
| Willard Stephen H | CHIEF EXECUTIVE OFFICER | 50,000 | Dec 19, 2022 | 0 |
| Javitt Daniel C. | 10% Owner | 9,634,793Indirect | Dec 1, 2022 | 0 |
| Glied Sharon | Director | – | Nov 22, 2022 | 0 |
| Besthof Robert | Interim CEO | 23,710 | Mar 10, 2022 | 0 |
| McMaster Herbert Raymond | Director | 18,300 | Nov 2, 2021 | 0 |
| Daigneault Alessandra | General Counsel & Secretary | 31,584 | Nov 2, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 18, 2024 (view filing) | Dec 17 | 1 day | Javitt Jonathan CChairman and Chief Scientist | PPurchase | +40.0K | $1.17 | +$46.8K | +89.6%84.6K after | |
| Sep 11, 2023 (view filing)9:19 AM ET | Aug 30 | 12 daysLate | Gorovitz AaronDirector | PPurchaseCommon Stock, par value $0.001 per share | +35.0K | $0.3199 | +$11.2K | +50.0%105.0K after | |
| Sep 11, 2023 (view filing)9:15 AM ET | Aug 30 | 12 daysLate | Hurvitz ChaimDirector | PPurchaseCommon Stock, par value $0.001 per share | +70.0K | $0.2875 | +$20.1K | +14.0%570.0K after | |
| Aug 24, 2023 (view filing)12:14 PM ET | Aug 23 | 1 day | Javitt Jonathan CChief Scientist | PPurchase | +100.0K | $0.33 | +$33.0K | +28.9%446.3K after | |
| Aug 23, 2023 (view filing)9:24 AM ET | Aug 22 | 1 day | Javitt Jonathan CChief Scientist | PPurchase | +200.0K | $0.322 | +$64.4K | +136.7%346.3K after | |
| Dec 19, 2022 (view filing) | Dec 16 | 3 days | Willard Stephen HCHIEF EXECUTIVE OFFICER | PPurchaseCommon Stock, par value $0.001 per share | +50.0K | $1.17 | +$58.5K | New position50.0K after | |
| Dec 19, 2022 (view filing) | Dec 16 | 3 days | Van Voorhees SethCHIEF FINANCIAL OFFICER | PPurchaseCommon Stock, par value $0.001 per share | +30.0K | $1.10 | +$33.0K | +183.6%46.3K after | |
| Dec 19, 2022 (view filing) | Nov 25 | 24 days | Van Voorhees SethCHIEF FINANCIAL OFFICER | PPurchaseCommon Stock, par value $0.001 per share | +16.3K | $1.11 | +$18.2K | New position16.3K after | Amended3 lots |
| Dec 9, 2022 (view filing) | Dec 7 | 2 days | Javitt Jonathan CDirector, 10% Owner | SSaleCommon Stock, par value $0.001 per share | −400.0K | $1.00 | −$400.0K | −3.0%12.9M after | |
| Dec 1, 2022 (view filing) | Nov 29-30 | 2 days | Javitt Daniel C.10% Owner | SSale | −22.2K | $1.50 | −$33.3K | −0.2%9.63M after | 2 lots |
| Nov 29, 2022 (view filing) | Nov 28 | 1 day | Flynn Patrick JohnDirector | PPurchaseCommon Stock, par value $0.001 per share | +10.0K | $1.25 | +$12.5K | +33.1%40.2K after | 4 lots |
| Nov 29, 2022 (view filing) | Nov 28 | 1 day | Flynn Patrick JohnDirector | PPurchaseCommon Stock, par value $0.001 per share | +1.75K | $1.25 | +$2.19K | New position1.75K after | |
| Nov 23, 2022 (view filing) | Nov 16-18 | 7 days | Hurvitz ChaimDirector | PPurchase | +500.0K | $1.03 | +$514.9K | New position500.0K after | Amended3 lots |
| Nov 18, 2022 (view filing) | Nov 16-17 | 2 days | Javitt Daniel C.10% Owner | SSale | −166.7K | $1.03 | −$171.1K | −1.7%9.66M after | 2 lots |
| Nov 15, 2022 (view filing) | Nov 11 | 4 days | Javitt Daniel C.10% Owner | SSale | −49.2K | $1.01 | −$49.7K | −0.5%9.82M after | |
| Aug 2, 2022 (view filing) | Jul 29 | 4 days | Javitt Daniel C.10% Owner | SSale | −784.1K | $1.01 | −$791.9K | −7.4%9.87M after | |
| Jun 7, 2022 (view filing) | Jun 3-7 | 4 days | Javitt Daniel C.10% Owner | SSale | −445.7K | $0.6825 | −$304.2K | −3.4%12.7M after | 3 lots |
| Jun 2, 2022 (view filing) | Jun 1 | 1 day | Javitt Jonathan CChief Scientist | PPurchase | +100.0K | $0.58 | +$58.0K | +215.8%146.3K after | Amended |
| Nov 2, 2021 (view filing)4:04 PM ET | Sep 15 | 48 daysLate | Besthof RobertChief Comm. & Patient Officer | SSale | −40.0K | $11.76 | −$470.4K | −62.8%23.7K after | |
| Nov 2, 2021 (view filing) | Aug 23 | 71 daysLate | Daigneault AlessandraGeneral Counsel & Secretary | SSale | −33.7K | $13.11 | −$442.0K | −100.0%0 after |